Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.77% | -4.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.77% | -4.88% | |||
| Cost of Revenue | 14.09% | -6.82% | |||
| Gross Profit | 10.10% | -3.43% | |||
| SG&A Expenses | -5.20% | -4.71% | |||
| Depreciation & Amortization | -5.77% | 0.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.83% | -4.46% | |||
| Operating Income | 127.08% | -1.32% | |||
| Income Before Tax | 113.14% | -36.92% | |||
| Income Tax Expenses | 83.92% | 188.10% | |||
| Earnings from Continuing Operations | 100.37% | -64.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.37% | -64.06% | |||
| EBIT | 127.08% | -1.32% | |||
| EBITDA | 1,749.17% | -6.25% | |||
| EPS Basic | 100.36% | -63.60% | |||
| Normalized Basic EPS | 156.63% | -48.92% | |||
| EPS Diluted | 100.36% | -57.29% | |||
| Normalized Diluted EPS | 155.50% | -48.92% | |||
| Average Basic Shares Outstanding | 0.10% | 0.29% | |||
| Average Diluted Shares Outstanding | 1.93% | 0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||